- Home
- GF vs ELEV Comparison
GF vs ELEV Comparison
Compare GF & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- ELEV
- Stock Information
- Founded
- GF 1990
- ELEV 2019
- Country
- GF Germany
- ELEV United States
- Employees
- GF N/A
- ELEV N/A
- Industry
- GF Investment Managers
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- GF Finance
- ELEV Health Care
- Exchange
- GF Nasdaq
- ELEV Nasdaq
- Market Cap
- GF 136.3M
- ELEV 155.7M
- IPO Year
- GF N/A
- ELEV 2021
- Fundamental
- Price
- GF $8.44
- ELEV $0.62
- Analyst Decision
- GF
- ELEV Strong Buy
- Analyst Count
- GF 0
- ELEV 5
- Target Price
- GF N/A
- ELEV $7.80
- AVG Volume (30 Days)
- GF 28.1K
- ELEV 659.3K
- Earning Date
- GF 01-01-0001
- ELEV 10-31-2024
- Dividend Yield
- GF 0.82%
- ELEV N/A
- EPS Growth
- GF N/A
- ELEV N/A
- EPS
- GF N/A
- ELEV N/A
- Revenue
- GF N/A
- ELEV N/A
- Revenue This Year
- GF N/A
- ELEV N/A
- Revenue Next Year
- GF N/A
- ELEV N/A
- P/E Ratio
- GF N/A
- ELEV N/A
- Revenue Growth
- GF N/A
- ELEV N/A
- 52 Week Low
- GF $7.38
- ELEV $0.36
- 52 Week High
- GF $9.41
- ELEV $5.83
- Technical
- Relative Strength Index (RSI)
- GF 48.17
- ELEV 23.41
- Support Level
- GF $8.31
- ELEV $0.61
- Resistance Level
- GF $8.38
- ELEV $0.64
- Average True Range (ATR)
- GF 0.06
- ELEV 0.06
- MACD
- GF -0.02
- ELEV 0.06
- Stochastic Oscillator
- GF 24.14
- ELEV 11.68
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a United States-based non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.